The estimated Net Worth of Niamh Louise Pellegrini is at least 5.94 百万$ dollars as of 10 March 2021. Ms. Pellegrini owns over 750 units of Nevro Corp stock worth over 188,249$ and over the last 10 years she sold NVRO stock worth over 718,408$. In addition, she makes 5,037,790$ as Chief Commercial Officer at Nevro Corp.
Sign up
Ms. Pellegrini NVRO stock SEC Form 4 insiders trading
Niamh has made over 10 trades of the Nevro Corp stock since 2020, according to the Form 4 filled with the SEC. Most recently she exercised 750 units of NVRO stock worth 48,713$ on 10 March 2021.
The largest trade she's ever made was selling 1,817 units of Nevro Corp stock on 22 October 2020 worth over 299,805$. On average, Niamh trades about 364 units every 8 days since 2014. As of 10 March 2021 she still owns at least 39,968 units of Nevro Corp stock.
You can see the complete history of Ms. Pellegrini stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Niamh Pellegrini biography
Niamh Louise Pellegrini serves as Chief Commercial Officer of the Company. From September 2018 to June 2019, Ms. Pellegrini was Vice President of Global Commercial Operations for Abbott Vascular. From April 2016 to September 2018, Ms. Pellegrini served as CEO and President at Autonomic Technologies, Inc. From October 2014 to October 2015, Ms. Pellegrini was President, North America at Thoratec Corporation. Prior to joining Thoratec Corporation, Ms. Pellegrini served in progressively responsible global business development, strategy and commercial roles at Johnson & Johnson. Ms. Pellegrini graduated from Santa Clara University with an M.B.A and a B.S. in finance.
What is the salary of Niamh Pellegrini?
As the Chief Commercial Officer of Nevro Corp, the total compensation of Niamh Pellegrini at Nevro Corp is 5,037,790$. There are 1 executives at Nevro Corp getting paid more, with D.Keith Grossman having the highest compensation of 13,877,700$.
How old is Niamh Pellegrini?
Niamh Pellegrini is 53, she's been the Chief Commercial Officer of Nevro Corp since 2019. There are 20 older and 4 younger executives at Nevro Corp. The oldest executive at Nevro Corp is Frank Fischer, 78, who is the Independent Director.
What's Niamh Pellegrini's mailing address?
Niamh's mailing address filed with the SEC is C/O ACUTUS MEDICAL, INC., 2210 FARADAY AVE., SUITE 100, CARLSBAD, CA, 92008.
Insiders trading at Nevro Corp
Over the last 10 years, insiders at Nevro Corp have traded over 298,472,982$ worth of Nevro Corp stock and bought 312,708 units worth 8,709,518$ . The most active insiders traders include Ali Behbahani、Holdings A/S Novo、& Johnson Johnson & Johnson.... On average, Nevro Corp executives and independent directors trade stock every 18 days with the average trade being worth of 161,002$. The most recent stock trade was executed by Shawn Mc Cormick on 7 June 2023, trading 7,500 units of NVRO stock currently worth 171,600$.
What does Nevro Corp do?
headquartered in redwood city, california, nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. nevro has developed and commercialized the senza spinal cord stimulation (scs) system, an evidence-based neuromodulation platform for the treatment of chronic pain. the senza system is the only scs system that delivers nevro's proprietary hf10 therapy. the nevro® senza® scs system received ce mark in 2010, tga approval in 2011, fda approval in 2015, and is commercially available in europe, australia, and the united states.
What does Nevro Corp's logo look like?
Complete history of Ms. Pellegrini stock trades at Nevro Corp、Acutus Medical
Nevro Corp executives and stock owners
Nevro Corp executives and other stock owners filed with the SEC include:
-
D.Keith Grossman,
Chairman of the Board, President, Chief Executive Officer -
Niamh Pellegrini,
Chief Commercial Officer -
Michael Carter,
Vice President - Global Sales -
Christopher Christoforou,
Vice President - Research and Development -
D. Keith Grossman,
Chairman, CEO & Pres -
Patrick Schmitz,
Vice President - Operations -
Kashif Rashid,
Chief Compliance Officer, General Counsel, Corporate Secretary -
Andrew H. Galligan,
Exec. Officer -
Kashif Rashid,
Gen. Counsel, Corp. Sec. & Chief Compliance Officer -
Roderick H. MacLeod,
Chief Financial Officer -
Elizabeth Weatherman,
Independent Director -
Kevin O'Boyle,
Independent Director -
Karen Prange,
Independent Director -
Michael DeMane,
Lead Independent Director -
Wilfred Jaeger,
Independent Director -
Shawn McCormick,
Independent Director -
Frank Fischer,
Independent Director -
Brad Vale,
Independent Director -
David Caraway,
Chief Medical Officer -
Donald Middlebrook,
Vice President - Clinical, Regulatory and Quality -
Juliet Cunningham,
Vice President - Investor Relations -
Lori Ciano,
Chief Human Resource Officer -
Roderick MacLeod,
Chief Financial Officer -
Dr. David Caraway,
Chief Medical Officer -
Lori M. Ciano,
Chief HR Officer -
Patrick Schmitz,
VP of Operations -
Jon R. Shear,
VP of Corp. Devel. -
Michael Collier Carter,
VP of Global Sales -
Julie D. Dewey,
Chief Corp. Communications & Investor Relations Officer -
Sridhar Kosaraju,
-
James Alecxih,
Vice President, Sales -
Lisa D Earnhardt,
Director -
Andre Walker,
Senior VP,Research&Development -
Ali Behbahani,
Director -
Kevin R Thornal,
President & CEO -
Rami Elghandour,
President -
Michael Enxing,
VP of Sales & Marketing -
Arch Management Iv, L.L.C.T...,
-
City Capital Llc Bay City C...,
-
Holdings A/S Novo,
10% owner -
Partners Ii Lp Amv,
-
City Capital Llc Bay City C...,
-
Nathan B Pliam,
Director -
& Johnson Johnson & Johnson...,
-
Balakrishnan Shankar,
VP, Operations -
Andrew H Galligan,
Chief Financial Officer -
Doug Alleavitch,
VP, Quality -
Kirt P Karros,
-
Christofer Christoforou,
SVP, Chief Operating Officer -
Greg Siller,
SVP & Chief Commercial Officer -
Richard B. Carter,
Chief Accounting Officer -
Susan E Siegel,